$6.03
+6.3%OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Chief Financial Officer
Compensation
$405,804
Chief Science Officer
Compensation
$552,014
Chief Technology Officer
Consulting Chief Medical Officer
President, Chief Executive Officer & Director
Compensation
$576,368
Scientific Advisor, Co-Chief Executive Officer of Biotime,Inc. & President of Biotime,Inc.
Senior Vice President of Business Operations
Vice President of Accounting, Treasurer, Controller & Principal Accounting Officer
Compensation
$280,627
Vice President, General Counsel & Secretary
During the last 12 months, insiders have purchased $3.25M worth of IMDX shares, with no selling activity reported.
291.6K
1.07M
0
0.00
+1.1M
+$1.07M
0
0.00
0
0.00
+0
+$0
653.0K
2.17M
0
0.00
+2.2M
+$2.17M
0
0.00
0
0.00
+0
+$0
Riggs Josh
Director, Officer: Ceo And President
$1.33M
Broadwood Partners, L.P.
10 Percent Owner
$1.07M
James Andrea S.
Officer: Chief Financial Officer
$783K
Liu James Yang
Officer: Vp Acct, Cntlr, Treasurer, Pao
$60K
No selling activity
Strong bullish signal with $3.25M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
4 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
IMDX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | May 14, 2025 | May 14, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | September 25, 2024 | September 25, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | April 29, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | July 10, 2023 | July 10, 2023 | 2023 | |
DEF 14A DEF 14A 2023 N/A | May 19, 2023 | May 19, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | June 08, 2022 | June 08, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | May 21, 2021 | May 21, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | May 26, 2020 | May 26, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | June 18, 2019 | June 18, 2019 | 2019 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.